CADL

Candel Therapeutics (CADL) shares declined even after the company reported encouraging data for its prostate cancer drug candidate. Retail investors are pushing back against the sell-off, with many calling the stock 'clearly a buy and hold' and arguing the market is overlooking the strength of the clinical results. The divergence between the positive data and the falling share price has become the focus of discussion among individual traders tracking the biotech.